outcomes examined (spirometry, clinical outcomes of exacerbation or sputum volume etc). The single study on long term outcomes showed no significant effect of inhaled steroids in any of the outcomes.
Authors' conclusions
The present review indicates that there is insufficient evidence to recommend the routine use of inhaled steroids in adults with stable state bronchiectasis. While a therapeutic trial may be justified in adults with difficult to control symptoms and in certain subgroups, this has to be balanced with adverse events especially if high doses are used. No recommendation can be made for the use of ICS in adults during an acute exacerbation or in children (for any state) as there were no studies.
P L A I N L A N G U A G E S U M M A R Y

Role of inhaled corticosteroids in management of non CF bronchiectasis
People with bronchiectasis have significant morbidity (e.g. cough, wheeze, sputum production) and have more rapid lung function decline. As asthma like symptoms are common in people with bronchiectasis, the routine use of inhaled corticosteroids is potentially beneficial in reducing exacerbations, symptoms and pulmonary decline. The review found that there is insufficient evidence for the routine use of inhaled corticosteroids in people with bronchiectasis. While inhaled corticosteroids may be beneficial in a subgroup of people with bronchiectasis, its use has to be balanced with adverse effects that include potential increase in commensal bacterial density in the sputum.
B A C K G R O U N D
Bronchiectasis, previously termed an 'orphan disease' is increasingly recognized as a major cause of respiratory morbidity especially in developing countries (Karadag 2005 , Karakoc 2001 and in some ethnic populations of affluent countries (Chang 2002 , Edwards 2003 , Singleton 2000 . The underlying aetiology of bronchiectasis varies from post recurrent respiratory infections to rare immune deficiencies. Other causes include primary ciliary dyskinesia, allergic bronchopulmonary aspergillosis and Mycobacterial infection (Shoemark 2007) . However, bronchiectasis is also a common pathway for a variety of diseases. Thus, the presence of bronchiectasis is also increasingly recognised in common (e.g. chronic obstructive pulmonary disease (COPD) (Patel 2004 , O'Brien 2000 and uncommon respiratory diseases (e.g. bronchiolitis obliterans (Chang 1998) and sarcoidosis (Lewis 2002)) as well non primary respiratory (e.g. autoimmune) diseases. When bronchiectasis is present with another underlying disorder, it increases the morbidity and mortality of the underlying diseases (Lewis 2002 , Keistinen 1997 . For example, in diseases like COPD the presence of bronchiectasis has been reported in 29-50% (Patel 2004 , O'Brien 2000 of cohorts and when present, increases the severity (Patel 2004) and frequency (Gursel 2006) of respiratory exacerbations. Thus, management of the symptoms and severity of bronchiectasis is important.
The dominant symptoms and signs of bronchiectasis are productive or wet cough, dyspnoea on exertion and presence of other respiratory signs (clubbing, chest wall deformity, respiratory noises such as wheeze or crepitations on auscultation). In the long term, pulmonary decline may occur (Keistinen 1997 , Twiss 2006 . In both children and adult cohort studies, asthma-like symptoms in people with bronchiectasis have been described and when present, is associated with accelerated pulmonary decline when compared to those with bronchiectasis but without asthma-like symptoms (Keistinen 1997 , Field 1969 .
Like patients with COPD, children and adults with bronchiectasis also suffer from recurrent acute exacerbations, some of whom require hospitalised treatment. Effective management regimes for bronchiectasis would reduce the frequency or severity of respiratory exacerbations, and/or the long term pulmonary decline. Based on Cole's 'vicious circle hypothesis', microbial colonization/ infection is important in the pathophysiology of bronchiectasis as it leads to bronchial obstruction and a normal or exaggerated inflammatory response (Cole 1986) . Neutrophilic airway inflammation is dominant in people with bronchiectasis and COPD and ICS is likely beneficial in people with COPD (Abramson 2006) . However use of ICS is associated with adverse events in children and adults that range from mild (candidiasis) to serious (adrenal insufficiency, osteoporosis, cataracts) events. Thus a systematic review on the efficacy of ICS in the management of children and adults with bronchiectasis would help guide clinical practice. This current review was significantly revised from a previous review (Ram 2000) .
O B J E C T I V E S
To evaluate the efficacy of inhaled corticosteroids (ICS) in children and adults with bronchiectasis; (a) during stable bronchiectasis; and for reducing (b) the severity and frequency of acute respiratory exacerbations and (c) long term pulmonary decline
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials using ICS in patients with bronchiectasis.
Types of participants
Children or adults with bronchiectasis (defined clinically or radiologically) not related to CF. Exclusion criteria: Participants with cystic fibrosis.
Types of interventions
All types of ICS.
Types of outcome measures
It was planned that attempts would have been made to obtain data on at least one of the following outcome measures: (A) for short term effectiveness (6 months or less) a) mean difference in bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, cough diary, etc), b) total numbers of days with respiratory symptoms c) mean difference in lung function indices (spirometry, other lung volumes, airway hyper-responsiveness) d) participants who had respiratory exacerbations and/or hospitalisations, e) total number of hospitalised days f ) mean difference in other objective indices (airway markers of inflammation, exhaled nitric oxide etc) g) proportions experiencing adverse effects of the intervention, (e.g. pharyngeal candidiasis, voice change, etc) (B) for medium to long term outcomes (> 6 months) h) radiology scores (high resolution computed tomography scans or chest radiograph) i) lung function j) clinical indices of bronchiectasis severity control (QOL, cough diary, Likert scale, visual analogue scale, level of interference of cough, etc), k) relevant airway markers of inflammation. l) mortality m) proportions experiencing adverse effects of the intervention, (e.g. adrenal insufficiency, cataracts, linear growth etc) 
Search methods for identification of studies
Data collection and analysis
Selection of studies
From the title, abstract, or descriptors, two reviewers (NK, AC) independently reviewed the literature searches to identify potentially relevant trials for full review. Searches of bibliographies and texts were conducted to identify additional studies. From the full text using specific criteria, the same two reviewers independently selected trials for inclusion. Agreement was measured using kappa statistics. Disagreement was resolved by consensus.
Data extraction and management
Trials that satisfied the inclusion criteria were reviewed and the following information recorded: study setting, year of study, source of funding, patient recruitment details (including number of eligible subjects), inclusion and exclusion criteria, other symptoms, randomisation and allocation concealment method, numbers of participants randomised, blinding (masking) of participants, care providers and outcome assessors, dose and type of intervention, duration of therapy, co-interventions, numbers of patients not followed up, reasons for withdrawals from study protocol (clinical, side-effects, refusal and other), details on side-effects of therapy, and whether intention-to-treat analyses were possible. Data were extracted on the outcomes described previously. Further information was requested from the authors but only two (Martinez 2006; Joshi 2004 ) responded with limited further information.
Assessment of risk of bias in included studies
We assessed the risk of bias for each of the studies included in the review independently (by two reviewers: NK & AC). Four components of quality were assessed:
1. Allocation concealment. Trials were scored as: Adequate concealment (low risk of bias); Unclear (unclear risk of bias); clearly inadequate concealment (high risk of bias).
2. Blinding. Trials were scored as: Participant and care provider and outcome assessor blinded and/or outcome assessor blinded (low risk of bias); unclear (unclear risk of bias); no blinding of outcome assessor (high risk of bias).
3. Reporting of participants by allocated group. Trials were scored as: Progress of all randomised participants in each group described (low risk of bias); Unclear or no mention of withdrawals or dropouts (high risk of bias) 4. Follow-up. Trials were scored as: Outcomes measured in >90% (where withdrawals due to complications and side-effects are categorised as treatment failures, low risk of bias), Grade B: Outcomes measured in 80-90%, Grade C: Unclear, Grade D: Outcomes measured in <80%. (Grade A = high quality). All assessments were included in Characteristics of included studies. Inter-reviewer reliability for the identification of high quality studies for each component was measured by the Kappa statistic.
Data synthesis
For the dichotomous outcome variables of each individual study, odds ratio (OR) was calculated using a modified intention-to-treat analysis. This analysis assumes that participants not available for outcome assessment have not improved (and probably represents a conservative estimate of effect). An initial qualitative comparison of all the individually analysed studies examined whether pooling of results (meta-analysis) is reasonable. This took into account differences in study populations, inclusion/exclusion criteria, interventions, outcome assessment, and estimated effect size. Results from studies that met the inclusion criteria and reported any of the outcomes of interest were included in the subsequent meta-analyses. The summary weighted risk ratio and 95% confidence interval (fixed effects model) were calculated (Cochrane statistical package, RevMan version 5). For cross-over studies, mean treatment differences were calculated from raw data, extracted or imputed and entered as fixed effects generic inverse variance (GIV) outcome, to provide summary weighted differences and 95% confidence intervals. In cross-over trials, only data from the first arm were included in meta-analysis when the data were combined with parallel studies (Elbourne 2002) . Numbers needed to treat (NNT) were calculated from the pooled OR and its 95% CI applied to a specified baseline risk using an online calculator (Cates 2003) . If studies reported outcomes using different measurement scales, the standardised mean difference was used. Any heterogeneity between the study results was described and tested to see if it reached statistical significance using a chi-squared test. The 95% confidence interval estimated using a random effects model were included whenever there are concerns about statistical heterogeneity.
Subgroup analysis and investigation of heterogeneity
The following a priori sub-group analysis was planned:
1. children (aged 18 years or less) and adults (>18 years) 2. dose of ICS; low (< 400 ug), moderate (400-800 ug), high (>800 ug) of budesonide equivalent 3. participant type (bronchiectasis as primary disease versus bronchiectasis as co-existent disease) 4. severity of bronchiectasis (based on lung function)
Sensitivity analysis
Sensitivity analyses were also planned to assess the impact of the potentially important factors on the overall outcomes: 1. study quality; 2. variation in the inclusion criteria; 3. differences in the medications used in the intervention and comparison groups; 4. differences in outcome measures; 5. analysis using random effects model; 6. analysis by "treatment received"; and 7. analysis by "intention-to-treat".
R E S U L T S Description of studies
Results of the search
From the 2006 and 2007 searches, the Airways Group specialised register/search identified 341 potentially relevant titles. After assessing the abstracts, 9 papers were obtained for consideration to be included into review. Three studies were excluded as ICS were not compared to placebo/ no treatment or were non-randomised studies or included subjects with pneumonia (Ghosh 2002; Monton 1999; ONeil 2004) Figure 1 ): Only data from a single study (Martinez 2006 which was a non-placebo study) could be displayed for these clinical parameters. Using ITT analysis, the number of subjects without sputum reduction as well as without improvement in dyspnoea (comparison 1.1.3 and 1.1.4) were significantly more in the control arm compared to the ICS arm. Subjects in the ICS group were significantly better than the control arm in the parameters of sputum volume reduction (OR of 7.69, 95%CI 1.92 to 30.70) and improvement in dyspnoea (OR of 3.33, 95%CI 1.17 to 9.43). There was no difference between groups for the clinical parameters of cough and wheeze. Although the Martinez 2006 study described a significant difference between groups for the number of participants experiencing reduced cough, we found no difference between groups when ITT analyses was performed. Also as the methodology of subjective cough measures was not a validated method, this data is not displayed as a forest plot. The data from Elborn 1992 though not included in the final analysis reported that the ICS group had a significant improvement in cough (p=0.02) but not wheeze and dyspnoea. None of the other studies reported these clinical outcomes. 
Risk of bias in included studies
Effects of interventions
Sensitivity analysis
As mentioned in comparisons 1 , removing the study with a poor quality score (no placebo) altered the results for FEV 1 and FVC from being significant to non significant between the ICS and control groups. On replacing the data from the fluticasone 1000µg arm of Martinez 2006 with the 500µg data in the meta-analysis, improvement in FEV 1 still favoured the ICS group with a mean difference (fixed) of 0.06 (95% CI 0.01, 0.10) though the effect was less, whereas the effect of ICS became non significant for the parameter of FVC (mean difference of 0.05, 95% CI -0.03, 0.12).
For the clinical data, the difference between the groups was still significant (favouring ICS group) for number of subjects without sputum volume reduction of >50% (OR of 0.19, 95%CI 0.05 to 0.79) though the variable of amount of sputum became non significant with MD (fixed) = -5.7 (95% CI -14.9, 3.5). For the outcomes of wheeze (OR of 0.65, 95%CI 0.22, 1.87) and cough (OR of 0.59, 95%CI 0.21, 1.62), there was still no difference between the groups. For the outcome of dyspnoea, actual data was not provided for the 500µg arm but the authors mentioned that there was no difference between groups. Hence it is assumed that the significant effect present for the 1000µg/day group (outcome 1.1.4) was no longer present for the 500µg/day group. Also, there was no change (i.e. no difference between groups) in the other outcome variables (diffusion capacity, residual volume, total lung capacity and exacerbation frequency).. Analysis using random effects did not alter the significance of any of the outcomes. None of the other planned sensitivity analysis were relevant.
D I S C U S S I O N
The meta-analysis based on six studies involving 303 adults has shown that use of high dose inhaled corticosteroids in patients with non CF bronchiectasis leads to a statistically significant though clinically minor improvement in the lung function indices of FEV 1 and FVC but not for peak flow. However when the study that was not placebo-controlled was excluded, there was no significant difference between groups in FEV 1 or FVC. Also there was no difference between groups for the other outcomes (exacerbations, sputum volume, clinical symptoms and FeNO).
The three studies (Joshi 2004; Martinez 2006; Tsang 1998) included in the short term effect of inhaled steroids in bronchiectasis showed a clinically small benefit of ICS on lung function parameters of FEV 1 and FVC. Two of the studies reported no significant difference between groups and the major contribution with a positive effect was that from Martinez 2006. Thus not surprisingly when Martinez's study was excluded based on quality (no placebo), the groups no longer differed. Also there was no difference between groups for PEFR, diffusion capacity and TLC. Nevertheless, Elborn 1992 data which could not be included in the meta-analysis showed a significant improvement in the FEV 1 as well as the 24 hour sputum volume in the ICS group compared to placebo group.
Data on the short term effect of ICS on clinical parameters of cough, wheeze, dyspnoea and sputum volume was available only from one study (Martinez 2006) . This showed a significant improvement in dyspnoea and sputum volume for the higher dose of fluticasone (1000µg/day) compared to the control group The lack of a placebo arm in this study makes assessment of these outcomes biased. The effect was also lost when data from 1000ug/day fluticasone was substituted by that for 500µg/day. Data on sputum volume from Tsang 1998 was not included in the analysis in view of clinically significant difference in the baseline values. Martinez 2006 showed a significant improvement in the quality of life score in the ICS group using the St George's Respiratory Questionnaire but was not included in the final analysis since it encompassed all the symptoms already included in the analysis.
Recurrent acute pulmonary exacerbations form part of the disease progression in patients with bronchiectasis and many of these exacerbations require hospital admission. Recurrent exacerbations not only lead to progressive deterioration of lung functions (Ellerman 1997) but are also one of the strong predictors of poor quality of life in bronchiectasis (Wilson 1997) . In this review, short term use of ICS did not significantly influence frequency of exacerbations . Prolonged ICS administration also did not significantly influence exacerbation frequency (Tsang 2005) .This becomes more relevant with the fact that ICS actually increased the bacterial density in the airways (Tsang 1998) and most exacerbations in bronchiectasis are likely of infective in origin. Though exacerbation was defined in a similar manner in all three studies, its definition in bronchiectasis, specially paediatric bronchiectasis, is not standardized (Chang 2008). For further research into prevention and treatment of bronchiectasis exacerbation to be useful, we need a consensus on the definition of exacerbation.
Administration of inhaled steroids for a longer duration (Tsang 2004; Tsang 2005) significantly increased the number of subjects who had a more than 20% reduction in the 24 hour sputum volume but did not have any beneficial effect in the other clinical or spirometric parameters. This lack of effect again suggests that infection and not pure inflammation, is probably the more relevant underlying pathogenic mechanism of disease progression in bronchiectasis.
Persistent inflammation plays a role in deterioration of lung function in bronchiectasis (Ip 1993 
Limitations of the Review
This systematic review is limited to 6 adult studies with variable designs, variable doses and length of study. Also data extraction was limited to only one to 4 studies for the outcomes examined. The small sample size (max 101) for the meta-analysis is also a significant limitation. The major contributor to the benefit of ICS was from a non-placebo controlled study.
A U T H O R S ' C O N C L U S I O N S Implications for practice
The present review indicates that there is insufficient evidence to recommend the routine use of inhaled steroids in adults with stable state bronchiectasis. The only study (Martinez 2006 ) that showed a benefit was a non-placebo controlled trial. In a second study benefit was found only with subgroup analysis and very high doses were utilised. While a therapeutic trial may be justified in patients with difficult to control symptoms, this has to be balanced with adverse events especially if high doses are used. In bronchiectasis, the adverse effect of ICS includes increased bacteria density and thus surveillance sputum bacteriology is recommended. No recommendation can be made for the use of ICS in adults during an acute exacerbation, or in children (for any state) as there were no studies.
Implications for research
Further studies are required to examine the effect of inhaled corticosteroids on short and long term outcomes for children and adults with non-CF bronchiectasis. Outcomes should include exacerbations (rate and hospital admission), symptoms, quality of life, lung function indices and inflammatory parameters and bacteriology. Studies are required in both stable state and during an acute exacerbation state. A validated and standardised definition of acute respiratory exacerbation is also required. Adult studies should clearly differentiate co-existent COPD as the presence of this may influence effect of ICS. A priori analysis for those with AHR should also be defined since its presence may influence ICS response.
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R E F E R E N C E S
References to studies included in this review
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Elborn 1992
Methods A prospective, double blind placebo controlled randomised cross over design with study duration of 6 weeks There were 5 patients who dropped out-unsure when these occurred. Two patients declined to take part in second limb of study No wash out period mentioned. 
Joshi 2004 (Continued)
Free of other bias? High risk Inclusion of patients who had a significant post bronchodilator response biased the study in favour of response to ICS since those with positive bronchodilator response are more likely to improve with ICS due to the asthma like reversibility in their airway
Martinez 2006
Methods Randomized (stratified for prior smoking habit in pack year), double blind (only for dose of steroid) non placebo controlled prospective trial with study duration 6 months Participants Of the 132 patients initially included in the study, 39 were excluded prior to randomisation (23 had high probability of asthma, 4 did not give consent, 1 had Down's syndrome and 3 each had psychiatric disorder, systemic steroids and had disease of significant severity). 93 patients enrolled in the study 7 drop outs during the study, 3 from the no steroid group and 2 each from the 500 µg and 1000µg group. Study completed in 86 patients No steroid group n = 28: mean age 70.9 (SD 6.1), 17 males. 500 µg/day fluticasone group n=29: mean age 66.4 (SD 12.6), 18 males. 1000 µg/day group n=29: mean age 70.9 (SD 6), 21 males Inclusion: All patients with HRCT diagnosed bronchiectasis diagnosed between 1993 and June 2003 in Requena General Hospital. The patients were required to be free from acute exacerbation for at least 4 weeks Exclusion: Patients with asthma, CF and on whom inhaled steroids could not be stopped
Interventions
Inhaled fluticasone 500 µg BD by MDI vs. 250 µg fluticasone BD vs. no treatment for 6 months Outcomes Baseline data collection started 6 months prior to randomisation. During this period data prospectively collected on number of acute exacerbations, antibiotic use and hospital admissions FEV 1 , FVC, TLC, RV and diffusion capacity measured few days prior to randomisation During randomisation visit, information collected on dyspnoea score, daily sputum production (average of sputum produced over 3 days); cough and need for short acting bronchodilator in the 1 month prior to randomisation, and health-related quality of life (HRQol) using the validated Spanish version of the St. George Respiratory Questionnaire (SGRQ) After randomisation, TLC, RV and diffusion capacity analysed again after 6 months. HRQol assessment at 3 and 6 months and all other tests at 1, 3 and 6 months >4 point change in SGRQ considered significant. > 1 point change is dyspnoea score considered significant Notes All comparisons made only between no steroids and 500 µg BD group. Additional information provided by the authors 
Risk of bias
W H A T ' S N E W
Last assessed as up-to-date: 26 October 2010.
Date Event Description
27 October 2010 New search has been performed Literature search run, no new studies identified. 
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